Rahul Winayak, MD, discusses the prognostic and predictive value of microbial dysbiosis in patients receiving CBM588 plus first-line immune checkpoint inhibitor-based regimens for metastatic renal cell carcinoma.
Rahul Winayak, MD
Advertisement
Articles by Rahul Winayak, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC
5